Pay Amgen $70 million, court tells Hospira in patent case

Hospira, a biosimilar injectables specialist now belonging to US pharma giant Pfizer, has been ordered to pay $70 million for infringing a patent belonging to Amgen relating to the anemia treatment Epogen (epoetin alfa).

A US jury upheld Amgen's claim that Hospira had violated information-sharing and advance-notice provisions of the Biologics Price Competition and Innovation Act in developing Retacrit, a biosimilar version of the anemia treatment.